Annual Report 2011 Active Biotech AB (publ)

LUND, SWEDEN--(Marketwire - April 17, 2012) -

Active Biotech's Annual Report 2011 (in Swedish) is now available for download at www.activebiotech.com.

The Annual Report will only be digitally distributed.

Lund, April 17, 2012

Active Biotech AB (publ)

Tomas Leanderson
President & CEO

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for Systemic Sclerosis and RhuDex® for RA. Please visit http://www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on April 17, 2012, at 10:00 a.m.

Annual Report 2011 Active Biotech AB (publ): http://hugin.info/1002/R/1602829/506506.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE [HUG#1602829]